Company Directory

Natural product-inspired small molecules for sexual and mental health

Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug development approaches. KH-001 completed Phase 1 safety studies in 2024 and is progressing to Phase 2 trials. A secondary pipeline targets mood disorders through novel neuropsychiatric compounds.

Human iPSC platform for neurodegenerative disease drug discovery

Talisman Therapeutics is a drug discovery company specialising in human induced pluripotent stem cell (iPSC) models of neurodegenerative disease. The company operates both an internal discovery pipeline, focused on Alzheimer's disease targets including lysosome biology, pathogenic protein reduction and microglial health, and an external collaboration programme. Talisman's iPSC-derived neural cell models are designed to improve the relevance and predictivity of early-stage compound screening.

Clinical-stage CNS drug discovery using human brain genomics

Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue samples, identifying novel drug targets. Combined with machine learning analysis, this approach supports a pipeline of CNS therapeutics targeting conditions including Parkinson's disease, Alzheimer's disease and ALS.

UK affiliate of global family-owned biopharmaceutical company

Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates across therapeutic areas including respiratory disease, cardiovascular disease, oncology, immunology, and metabolic disorders. It is a member of the ABPI and one of the largest pharmaceutical employers in Berkshire.

Antibody discovery platform identifying therapeutics from resilient individuals

Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases. The company's lead programme for amyotrophic lateral sclerosis entered Phase 1 trials following a licensing agreement with Eli Lilly. Alchemab operates from London with research laboratories in Cambridge.

Clinical trial delivery for Alzheimer's and neurodegenerative disease

Scottish Brain Sciences is a contract research organisation building and operating clinical trial infrastructure for Alzheimer's disease and other neurodegenerative conditions. Working with pharmaceutical sponsors, it delivers trial screening, patient recruitment, and study conduct at dedicated clinical sites in Edinburgh and Aberdeen. Its capabilities span blood biomarker testing, neuroimaging, and cognitive assessment, enabling early detection and participant identification for disease-modifying therapy trials.

Real-world mental health and dementia data platform for drug development

Akrivia Health is a software company providing a real-world data and AI platform for neuroscience research and drug development. Its dataset of de-identified electronic health records from 6.3 million patients across 20 NHS Trusts covers mental health and dementia conditions, enriched through proprietary natural language processing. Commercial applications include health economics and outcomes research, clinical trial patient recruitment, pharmacovigilance, and drug discovery target identification.

Multimodal small molecule therapeutics for neurodegenerative disease

Elixa MediScience is a UK drug discovery company developing novel small molecule compounds designed to slow the progression and delay the onset of neurodegenerative diseases including Alzheimer's, Parkinson's and multiple sclerosis. The company's approach targets multiple pathophysiological mechanisms simultaneously, addressing the limitations of existing single-pathway strategies. Elixa operates as a virtual biotech, outsourcing all R&D activity, with a strategy of advancing lead candidates to first-in-human readiness before seeking development and commercialisation partners.

C. elegans whole-organism platform for preclinical drug and compound screening

Magnitude Biosciences Limited is a contract research organisation providing preclinical drug discovery and compound screening services using Caenorhabditis elegans as a whole-organism model. Its proprietary biophotonics platform enables automated, high-throughput, non-invasive monitoring of health and lifespan metrics across large worm populations, supporting compound library screening, pathway analysis, microbiome assessment, and toxicology studies. The platform accelerates early compound triage for pharmaceutical, biotechnology, and nutrition clients, reducing reliance on mammalian models.

AI-driven neural data platform for bioelectronic medicine

BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation therapies and neural digital therapeutics. BIOS serves pharmaceutical and medical device partners, academic research institutions, and NHS clinical programmes targeting cardiovascular, neurological, and autoimmune conditions.

Precision medicine biotech targeting psychiatric and neurological conditions

Monument Therapeutics is a clinical-stage biotechnology company applying precision medicine to CNS drug development. The company uses proprietary digital biomarkers to stratify patients by shared neurobiological profiles, matching them to targeted small molecule treatments. Its pipeline addresses conditions of high unmet need, including cognitive impairment associated with schizophrenia and neuroinflammation. By combining patient stratification with novel reformulations of well-characterised CNS-active compounds, Monument aims to improve clinical trial success rates in psychiatry and neurology.

Mitochondrial sulfide-donor therapeutics for obesity and myopathies

MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic dysfunction and muscle disease. Its lead programme is an injectable mitochondria-targeted sulfide donor designed to achieve fat loss without lean mass loss, positioning it as a differentiated alternative to GLP-1 receptor agonists. Preclinical studies have also demonstrated efficacy in models of Duchenne muscular dystrophy and Alzheimer's disease.